MaaT Pharma publishes 2024 half-year results and provides a business update

Regulatory News:

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies^TM (MET), focused on improving survival rates for cancer patients through immune modulation, today announced its half-year results for the six-month period ended June 30, 2024 and provided a business overview.

“Building on the positive data for MaaT013 presented at the EBMT Congress in April 2024 and the success of our recent fundraise, we have dedicated the first half of 2024 to pursuing recruitment and preparing for the topline results from our ongoing Phase 3 clinical trial for MaaT013. This trial is designed to address the urgent unmet medical need for patients with acute graft-versus-host disease who are refractory to current therapies. Currently, patients requiring third-line treatment options face an 85% one-year mortality rate. Furthermore, by extending our cash runway for an additional quarter, we are well-positioned to achieve our near-term milestones,” said Siân Crouzet, Chief Financial Officer of MaaT Pharma.